BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. Cell. 2016;165:276-287. [PMID: 27058662 DOI: 10.1016/j.cell.2016.03.001] [Cited by in Crossref: 203] [Cited by in F6Publishing: 178] [Article Influence: 40.6] [Reference Citation Analysis]
Number Citing Articles
1 Qi JL, He JR, Jin SM, Yang X, Bai HM, Liu CB, Ma YB. P. aeruginosa Mediated Necroptosis in Mouse Tumor Cells Induces Long-Lasting Systemic Antitumor Immunity. Front Oncol 2020;10:610651. [PMID: 33643911 DOI: 10.3389/fonc.2020.610651] [Reference Citation Analysis]
2 Ambrosio MR, Vernillo R, De Carolis S, Carducci A, Mundo L, Ginori A, Rocca BJ, Nardone V, Lucenti Fei A, Carfagno T, Lazzi S, Cricca M, Tosi P. Putative Role of Circulating Human Papillomavirus DNA in the Development of Primary Squamous Cell Carcinoma of the Middle Rectum: A Case Report. Front Oncol 2019;9:93. [PMID: 30847303 DOI: 10.3389/fonc.2019.00093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37:559-569. [PMID: 30650045 DOI: 10.1200/jco.18.01010] [Cited by in Crossref: 189] [Cited by in F6Publishing: 119] [Article Influence: 94.5] [Reference Citation Analysis]
4 Hurez V, Padrón Á, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Exp Gerontol 2018;107:27-36. [PMID: 28987644 DOI: 10.1016/j.exger.2017.10.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
5 Bingula R, Filaire M, Radosevic-Robin N, Bey M, Berthon JY, Bernalier-Donadille A, Vasson MP, Filaire E. Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. J Oncol 2017;2017:5035371. [PMID: 29075294 DOI: 10.1155/2017/5035371] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 17.3] [Reference Citation Analysis]
6 Kiss B, Mikó E, Sebő É, Toth J, Ujlaki G, Szabó J, Uray K, Bai P, Árkosy P. Oncobiosis and Microbial Metabolite Signaling in Pancreatic Adenocarcinoma. Cancers (Basel) 2020;12:E1068. [PMID: 32344895 DOI: 10.3390/cancers12051068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
7 Beckmann JS, Lew D. Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities. Genome Med 2016;8:134. [PMID: 27993174 DOI: 10.1186/s13073-016-0388-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 49] [Article Influence: 15.8] [Reference Citation Analysis]
8 De Palma FDE, D'Argenio V, Pol J, Kroemer G, Maiuri MC, Salvatore F. The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. Cancers (Basel). 2019;11. [PMID: 31330830 DOI: 10.3390/cancers11071017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 19.0] [Reference Citation Analysis]
9 Quandt J, Arnovitz S, Haghi L, Woehlk J, Mohsin A, Okoreeh M, Mathur PS, Emmanuel AO, Osman A, Krishnan M, Morin SB, Pearson AT, Sweis RF, Pekow J, Weber CR, Khazaie K, Gounari F. Wnt-β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nat Immunol 2021;22:471-84. [PMID: 33664518 DOI: 10.1038/s41590-021-00889-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
10 Garg AD, Agostinis P. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunol Rev 2017;280:126-48. [PMID: 29027218 DOI: 10.1111/imr.12574] [Cited by in Crossref: 144] [Cited by in F6Publishing: 124] [Article Influence: 48.0] [Reference Citation Analysis]
11 Lipinski S, Tiemann K. Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumor-Immune Interactions. Int J Mol Sci 2021;22:3374. [PMID: 33806053 DOI: 10.3390/ijms22073374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW, Meurice G, Walter S, Fritsche J, Weinschenk T, Rammensee HG, Melief C, Thibault P, Perreault C, Pol J, Zitvogel L, Senovilla L, Kroemer G. Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol Rev 2017;280:165-74. [PMID: 29027230 DOI: 10.1111/imr.12582] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]
13 Jacqueline C, Finn OJ. Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention. Semin Immunol 2020;47:101394. [PMID: 32273212 DOI: 10.1016/j.smim.2020.101394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Hangai S, Kimura Y, Taniguchi T, Yanai H. Signal-transducing innate receptors in tumor immunity. Cancer Sci 2021;112:2578-91. [PMID: 33570784 DOI: 10.1111/cas.14848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Huang X, Pan J, Xu F, Shao B, Wang Y, Guo X, Zhou S. Bacteria-Based Cancer Immunotherapy. Adv Sci (Weinh) 2021;8:2003572. [PMID: 33854892 DOI: 10.1002/advs.202003572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kuczma MP, Ding ZC, Li T, Habtetsion T, Chen T, Hao Z, Bryan L, Singh N, Kochenderfer JN, Zhou G. The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. Oncotarget. 2017;8:111931-111942. [PMID: 29340102 DOI: 10.18632/oncotarget.22953] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
17 Yu Q, Jia A, Li Y, Bi Y, Liu G. Microbiota regulate the development and function of the immune cells. Int Rev Immunol 2018;37:79-89. [PMID: 29425062 DOI: 10.1080/08830185.2018.1429428] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
18 Ceppi F, Beck-Popovic M, Bourquin JP, Renella R. Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. Eur J Pediatr 2017;176:1163-72. [PMID: 28803259 DOI: 10.1007/s00431-017-2982-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
19 Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 2016;16:525-37. [PMID: 27388699 DOI: 10.1038/nrc.2016.56] [Cited by in Crossref: 227] [Cited by in F6Publishing: 194] [Article Influence: 45.4] [Reference Citation Analysis]
20 Zou R, Wang Y, Ye F, Zhang X, Wang M, Cui S. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clin Transl Oncol 2021. [PMID: 34002348 DOI: 10.1007/s12094-021-02637-2] [Reference Citation Analysis]
21 Ding L, Dong HY, Zhou TR, Wang YH, Yan T, Li JC, Wang ZY, Li J, Liang C. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Cancer Med 2021. [PMID: 34382349 DOI: 10.1002/cam4.4190] [Reference Citation Analysis]
22 Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res 2020;30:492-506. [PMID: 32433595 DOI: 10.1038/s41422-020-0332-7] [Cited by in Crossref: 226] [Cited by in F6Publishing: 173] [Article Influence: 226.0] [Reference Citation Analysis]
23 Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, Borghaei H, Edelman MJ, Boumber Y. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Adv Ther 2019;36:2638-78. [PMID: 31410780 DOI: 10.1007/s12325-019-01051-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 28.0] [Reference Citation Analysis]
24 Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. J Thorac Oncol 2021;16:1086-98. [PMID: 33845212 DOI: 10.1016/j.jtho.2021.03.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Denaro N, Merlano MC. In response to Ham et al.: Antibiotics effect on outcome in head and neck cancer. European Journal of Cancer 2019;117:119-20. [DOI: 10.1016/j.ejca.2019.05.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Semin Cancer Biol 2018;52:189-97. [PMID: 29501787 DOI: 10.1016/j.semcancer.2018.02.010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 16.3] [Reference Citation Analysis]
27 Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L. Immuno-oncology-101: overview of major concepts and translational perspectives. Semin Cancer Biol 2018;52:1-11. [PMID: 29428479 DOI: 10.1016/j.semcancer.2018.02.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
28 Dougé A, Bay JO, Ravinet A, Scanzi J. [Intestinal microbiota and allogeneic stem cell transplantation]. Bull Cancer 2020;107:72-83. [PMID: 31582175 DOI: 10.1016/j.bulcan.2019.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Abid MB. Could the menagerie of the gut microbiome really cure cancer? Hope or hype. J Immunother Cancer 2019;7:92. [PMID: 30940203 DOI: 10.1186/s40425-019-0561-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
30 Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants of tumour immunity. Nat Rev Cancer 2019;19:215-27. [PMID: 30867580 DOI: 10.1038/s41568-019-0125-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 49] [Article Influence: 18.5] [Reference Citation Analysis]
31 Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-150. [PMID: 30755690 DOI: 10.1038/s41568-019-0116-x] [Cited by in Crossref: 726] [Cited by in F6Publishing: 621] [Article Influence: 363.0] [Reference Citation Analysis]
32 Anderson KG, Stromnes IM, Greenberg PD. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell 2017;31:311-25. [PMID: 28292435 DOI: 10.1016/j.ccell.2017.02.008] [Cited by in Crossref: 250] [Cited by in F6Publishing: 221] [Article Influence: 62.5] [Reference Citation Analysis]
33 Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS; Blood and Marrow Transplant Clinical Trials Network. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant 2018;24:1322-40. [PMID: 29471034 DOI: 10.1016/j.bbmt.2018.02.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 15.0] [Reference Citation Analysis]
34 Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol 2021;10:18. [PMID: 33653420 DOI: 10.1186/s40164-021-00211-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
35 Tsilimigras MC, Fodor A, Jobin C. Carcinogenesis and therapeutics: The microbiota perspective. Nat Microbiol. 2017;2:17008. [PMID: 28225000 DOI: 10.1038/nmicrobiol.2017.8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 15.5] [Reference Citation Analysis]
36 Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R. The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clin Transl Med 2019;8:9. [PMID: 30887236 DOI: 10.1186/s40169-019-0225-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 22.0] [Reference Citation Analysis]
37 Britton N, Elbehairy AF, Mensink-Bout SM, Blondeel A, Liu Y, Cruz J, De Brandt J. European Respiratory Society International Congress 2020: highlights from best-abstract awardees. Breathe (Sheff) 2020;16:200270. [PMID: 33664840 DOI: 10.1183/20734735.0270-2020] [Reference Citation Analysis]
38 Wahid M, Dar SA, Jawed A, Mandal RK, Akhter N, Khan S, Khan F, Jogiah S, Rai AK, Rattan R. Microbes in gynecologic cancers: Causes or consequences and therapeutic potential. Semin Cancer Biol 2021:S1044-579X(21)00208-X. [PMID: 34302959 DOI: 10.1016/j.semcancer.2021.07.013] [Reference Citation Analysis]
39 Elmore LW, Greer SF, Daniels EC, Saxe CC, Melner MH, Krawiec GM, Cance WG, Phelps WC. Blueprint for cancer research: Critical gaps and opportunities. CA Cancer J Clin 2021;71:107-39. [PMID: 33326126 DOI: 10.3322/caac.21652] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Dutta A, Uno H, Lorenz DR, Wolinsky SM, Gabuzda D. Low T-cell subsets prior to development of virus-associated cancer in HIV-seronegative men who have sex with men. Cancer Causes Control 2018;29:1131-42. [PMID: 30315476 DOI: 10.1007/s10552-018-1090-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Sári Z, Mikó E, Kovács T, Jankó L, Csonka T, Lente G, Sebő É, Tóth J, Tóth D, Árkosy P, Boratkó A, Ujlaki G, Török M, Kovács I, Szabó J, Kiss B, Méhes G, Goedert JJ, Bai P. Indolepropionic Acid, a Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing Oxidative Stress. Cancers (Basel) 2020;12:E2411. [PMID: 32854297 DOI: 10.3390/cancers12092411] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
42 Ma K, Jin Q, Wang M, Li X, Zhang Y. Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. Expert Rev Mol Diagn 2019;19:517-29. [PMID: 31079502 DOI: 10.1080/14737159.2019.1617702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Pieniążek M, Pawlak P, Radecka B. Early palliative care of non-small cell lung cancer in the context of immunotherapy. Oncol Lett 2020;20:396. [PMID: 33193856 DOI: 10.3892/ol.2020.12259] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Eggermont AMM, Crittenden M, Wargo J. Combination Immunotherapy Development in Melanoma. Am Soc Clin Oncol Educ Book 2018;38:197-207. [PMID: 30231333 DOI: 10.1200/EDBK_201131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
45 Sipos A, Ujlaki G, Mikó E, Maka E, Szabó J, Uray K, Krasznai Z, Bai P. The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Mol Med 2021;27:33. [PMID: 33794773 DOI: 10.1186/s10020-021-00295-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
46 Katayama Y, Yamada T, Tanimura K, Yoshimura A, Takeda T, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. Thorac Cancer 2019;10:526-32. [PMID: 30666802 DOI: 10.1111/1759-7714.12969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
47 Cao X. Integrative strategy for improving cancer immunotherapy. J Mol Med (Berl) 2016;94:485-7. [PMID: 27114349 DOI: 10.1007/s00109-016-1424-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Goodman B, Gardner H. The microbiome and cancer. J Pathol. 2018;244:667-676. [PMID: 29377130 DOI: 10.1002/path.5047] [Cited by in Crossref: 76] [Cited by in F6Publishing: 57] [Article Influence: 25.3] [Reference Citation Analysis]
49 Trimaglio G, Tilkin-Mariamé AF, Feliu V, Lauzéral-Vizcaino F, Tosolini M, Valle C, Ayyoub M, Neyrolles O, Vergnolle N, Rombouts Y, Devaud C. Colon-specific immune microenvironment regulates cancer progression versus rejection. Oncoimmunology 2020;9:1790125. [PMID: 32923152 DOI: 10.1080/2162402X.2020.1790125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
50 Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018;72:449-59. [PMID: 28851100 DOI: 10.1111/his.13375] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
51 Andrews MC, Reuben A, Gopalakrishnan V, Wargo JA. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Front Immunol 2018;9:946. [PMID: 29780391 DOI: 10.3389/fimmu.2018.00946] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
52 Vernocchi P, Gili T, Conte F, Del Chierico F, Conta G, Miccheli A, Botticelli A, Paci P, Caldarelli G, Nuti M, Marchetti P, Putignani L. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer. Int J Mol Sci 2020;21:E8730. [PMID: 33227982 DOI: 10.3390/ijms21228730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Uribe-Herranz M, Rafail S, Beghi S, Gil-de-Gómez L, Verginadis I, Bittinger K, Pustylnikov S, Pierini S, Perales-Linares R, Blair IA, Mesaros CA, Snyder NW, Bushman F, Koumenis C, Facciabene A. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Invest 2020;130:466-79. [PMID: 31815742 DOI: 10.1172/JCI124332] [Cited by in Crossref: 46] [Cited by in F6Publishing: 24] [Article Influence: 46.0] [Reference Citation Analysis]
54 Yuan M, Li D, Zhang Z, Sun H, An M, Wang G. Endometriosis induces gut microbiota alterations in mice. Hum Reprod 2018;33:607-16. [PMID: 29462324 DOI: 10.1093/humrep/dex372] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 18.0] [Reference Citation Analysis]
55 Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N, Humeau J, Buque A, Kepp O, Zitvogel L, André F, Mathieu MC, Delaloge S, Kroemer G. The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology 2016;5:e1218106. [PMID: 27853639 DOI: 10.1080/2162402X.2016.1218106] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
56 Zhang S, Yang Y, Weng W, Guo B, Cai G, Ma Y, Cai S. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res 2019;38:14. [PMID: 30630498 DOI: 10.1186/s13046-018-0985-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 20.5] [Reference Citation Analysis]
57 Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun 2017;8:14600. [PMID: 28300057 DOI: 10.1038/ncomms14600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
58 Travert C, Barlesi F, Greillier L, Tomasini P. Immune Oncology Biomarkers in Lung Cancer: an Overview. Curr Oncol Rep 2020;22:107. [PMID: 32803433 DOI: 10.1007/s11912-020-00970-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer 2016;16:759-73. [PMID: 27687979 DOI: 10.1038/nrc.2016.91] [Cited by in Crossref: 162] [Cited by in F6Publishing: 135] [Article Influence: 32.4] [Reference Citation Analysis]
60 Mitsuhashi A, Okuma Y. Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. Clin Transl Oncol 2018;20:966-74. [PMID: 29313208 DOI: 10.1007/s12094-017-1827-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
61 Xu C, Ruan B, Jiang Y, Xue T, Wang Z, Lu H, Wei M, Wang S, Ye Z, Zhai D, Wang L, Lu Z. Antibiotics-induced gut microbiota dysbiosis promotes tumor initiation via affecting APC-Th1 development in mice. Biochem Biophys Res Commun 2017;488:418-24. [PMID: 28506830 DOI: 10.1016/j.bbrc.2017.05.071] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
62 Wu Z, Liu J, Dai R, Wu S. Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci 2021;64:512-33. [PMID: 32926318 DOI: 10.1007/s11427-020-1768-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Guipaud O, Jaillet C, Clément-Colmou K, François A, Supiot S, Milliat F. The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy. Br J Radiol 2018;91:20170762. [PMID: 29630386 DOI: 10.1259/bjr.20170762] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
64 Pang X, Tang YJ, Ren XH, Chen QM, Tang YL, Liang XH. Microbiota, Epithelium, Inflammation, and TGF-β Signaling: An Intricate Interaction in Oncogenesis. Front Microbiol 2018;9:1353. [PMID: 29997586 DOI: 10.3389/fmicb.2018.01353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
65 Estevinho MM, Rocha C, Correia L, Lago P, Ministro P, Portela F, Trindade E, Afonso J, Peyrin-Biroulet L, Magro F; GEDII (Portuguese IBD Group). Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. Clin Gastroenterol Hepatol 2020;18:1054-69. [PMID: 31526845 DOI: 10.1016/j.cgh.2019.08.063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
66 Kovács P, Csonka T, Kovács T, Sári Z, Ujlaki G, Sipos A, Karányi Z, Szeőcs D, Hegedűs C, Uray K, Jankó L, Kiss M, Kiss B, Laoui D, Virág L, Méhes G, Bai P, Mikó E. Lithocholic Acid, a Metabolite of the Microbiome, Increases Oxidative Stress in Breast Cancer. Cancers (Basel) 2019;11:E1255. [PMID: 31461945 DOI: 10.3390/cancers11091255] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
67 Sári Z, Mikó E, Kovács T, Boratkó A, Ujlaki G, Jankó L, Kiss B, Uray K, Bai P. Indoxylsulfate, a Metabolite of the Microbiome, Has Cytostatic Effects in Breast Cancer via Activation of AHR and PXR Receptors and Induction of Oxidative Stress. Cancers (Basel) 2020;12:E2915. [PMID: 33050543 DOI: 10.3390/cancers12102915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
68 Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731-e741. [PMID: 29208439 DOI: 10.1016/s1470-2045(17)30607-1] [Cited by in Crossref: 297] [Cited by in F6Publishing: 166] [Article Influence: 74.3] [Reference Citation Analysis]
69 Chen H, Yang M, Wang Q, Song F, Li X, Chen K. The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. Oncoimmunology 2019;8:1608132. [PMID: 31413919 DOI: 10.1080/2162402X.2019.1608132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
70 Huang M, Lu JJ, Ding J. Natural Products in Cancer Therapy: Past, Present and Future. Nat Prod Bioprospect 2021;11:5-13. [PMID: 33389713 DOI: 10.1007/s13659-020-00293-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
71 Finn OJ. A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. J Immunol 2018;200:385-91. [PMID: 29311379 DOI: 10.4049/jimmunol.1701302] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 17.3] [Reference Citation Analysis]
72 Tucker MD, Rini BI. Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. Cancers (Basel) 2020;12:E2662. [PMID: 32961934 DOI: 10.3390/cancers12092662] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
73 Wong MK, Barbulescu P, Coburn B, Reguera-Nuñez E. Therapeutic interventions and mechanisms associated with gut microbiota-mediated modulation of immune checkpoint inhibitor responses. Microbes Infect 2021;23:104804. [PMID: 33652120 DOI: 10.1016/j.micinf.2021.104804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O, Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD; Australian Pancreatic Cancer Genome Initiative., Garvan Institute of Medical Research., Prince of Wales Hospital., Royal North Shore Hospital., University of Glasgow., St Vincent’s Hospital., QIMR Berghofer Medical Research Institute., University of Melbourne, Centre for Cancer Research., University of Queensland, Institute for Molecular Bioscience., Bankstown Hospital., Liverpool Hospital., Royal Prince Alfred Hospital, Chris O’Brien Lifehouse., Westmead Hospital., Fremantle Hospital., St John of God Healthcare., Royal Adelaide Hospital., Flinders Medical Centre., Envoi Pathology., Princess Alexandria Hospital., Austin Hospital., Johns Hopkins Medical Institutes., ARC-Net Centre for Applied Research on Cancer. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 2017;551:512-6. [PMID: 29132146 DOI: 10.1038/nature24462] [Cited by in Crossref: 443] [Cited by in F6Publishing: 361] [Article Influence: 110.8] [Reference Citation Analysis]
75 Gaines S, Shao C, Hyman N, Alverdy JC. Gut microbiome influences on anastomotic leak and recurrence rates following colorectal cancer surgery. Br J Surg. 2018;105:e131-e141. [PMID: 29341151 DOI: 10.1002/bjs.10760] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 20.0] [Reference Citation Analysis]
76 Tosolini M, Pont F, Poupot M, Vergez F, Nicolau-Travers ML, Vermijlen D, Sarry JE, Dieli F, Fournié JJ. Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology 2017;6:e1284723. [PMID: 28405516 DOI: 10.1080/2162402X.2017.1284723] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 15.3] [Reference Citation Analysis]
77 Giannone G, Ghisoni E, Genta S, Scotto G, Tuninetti V, Turinetto M, Valabrega G. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. Int J Mol Sci 2020;21:E4414. [PMID: 32575899 DOI: 10.3390/ijms21124414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
78 Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, Weber JS, Osman I, Ahn J. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med 2019;11:61. [PMID: 31597568 DOI: 10.1186/s13073-019-0672-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
79 Yan S, Luo Z, Li Z, Wang Y, Tao J, Gong C, Liu X. Improving Cancer Immunotherapy Outcomes Using Biomaterials. Angew Chem Int Ed 2020;59:17332-43. [DOI: 10.1002/anie.202002780] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
80 Fukui H. Improve gut microbiome: a new horizon of cancer therapy. Hepatobiliary Surg Nutr. 2017;6:424-428. [PMID: 29312982 DOI: 10.21037/hbsn.2017.08.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
81 Schneider G, Schmidt-Supprian M, Rad R, Saur D. Tissue-specific tumorigenesis: context matters. Nat Rev Cancer 2017;17:239-53. [PMID: 28256574 DOI: 10.1038/nrc.2017.5] [Cited by in Crossref: 149] [Cited by in F6Publishing: 115] [Article Influence: 37.3] [Reference Citation Analysis]
82 Theilmann MC, Goh YJ, Nielsen KF, Klaenhammer TR, Barrangou R, Abou Hachem M. Lactobacillus acidophilus Metabolizes Dietary Plant Glucosides and Externalizes Their Bioactive Phytochemicals. mBio 2017;8:e01421-17. [PMID: 29162708 DOI: 10.1128/mBio.01421-17] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 10.8] [Reference Citation Analysis]
83 Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updat 2020;53:100718. [PMID: 32736034 DOI: 10.1016/j.drup.2020.100718] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
84 Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Eur Urol Focus 2018;4:442-54. [PMID: 29056275 DOI: 10.1016/j.euf.2017.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Karabulutoglu M, Finnon R, Imaoka T, Friedl AA, Badie C. Influence of diet and metabolism on hematopoietic stem cells and leukemia development following ionizing radiation exposure. Int J Radiat Biol 2019;95:452-79. [PMID: 29932783 DOI: 10.1080/09553002.2018.1490042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
86 Tripodi L, Vitale M, Cerullo V, Pastore L. Oncolytic Adenoviruses for Cancer Therapy. Int J Mol Sci 2021;22:2517. [PMID: 33802281 DOI: 10.3390/ijms22052517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Bouferraa Y, Chedid A, Amhaz G, El Lakkiss A, Mukherji D, Temraz S, Shamseddine A. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. Int J Mol Sci 2021;22:8036. [PMID: 34360802 DOI: 10.3390/ijms22158036] [Reference Citation Analysis]
88 Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol 2017;15:465-78. [PMID: 28529325 DOI: 10.1038/nrmicro.2017.44] [Cited by in Crossref: 205] [Cited by in F6Publishing: 158] [Article Influence: 51.3] [Reference Citation Analysis]
89 Routy B, Letendre C, Enot D, Chénard-Poirier M, Mehraj V, Séguin NC, Guenda K, Gagnon K, Woerther PL, Ghez D, Lachance S. The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. Oncoimmunology 2017;6:e1258506. [PMID: 28197380 DOI: 10.1080/2162402X.2016.1258506] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 7.8] [Reference Citation Analysis]
90 Li D, Toji S, Watanabe K, Torigoe T, Tsukahara T. Identification of novel human leukocyte antigen-A*11:01-restricted cytotoxic T-lymphocyte epitopes derived from osteosarcoma antigen papillomavirus binding factor. Cancer Sci 2019;110:1156-68. [PMID: 30767336 DOI: 10.1111/cas.13973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
91 Kinlen LJ, Gilham C, Ray R, Thomas DB, Peto J. Cohabitation, infection and breast cancer risk. Int J Cancer 2021;148:1408-18. [PMID: 32984953 DOI: 10.1002/ijc.33319] [Reference Citation Analysis]
92 Kovács T, Mikó E, Vida A, Sebő É, Toth J, Csonka T, Boratkó A, Ujlaki G, Lente G, Kovács P, Tóth D, Árkosy P, Kiss B, Méhes G, Goedert JJ, Bai P. Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors. Sci Rep 2019;9:1300. [PMID: 30718646 DOI: 10.1038/s41598-018-37664-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 21.0] [Reference Citation Analysis]
93 Blidner AG, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Anderson R. Cancer immunotherapy-related adverse events: causes and challenges. Support Care Cancer 2020;28:6111-7. [PMID: 32857220 DOI: 10.1007/s00520-020-05705-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
94 Rossi P, Difrancia R, Quagliariello V, Savino E, Tralongo P, Randazzo CL, Berretta M. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget 2018;9:24837-56. [PMID: 29872510 DOI: 10.18632/oncotarget.24984] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
95 Haibe Y, El Husseini Z, El Sayed R, Shamseddine A. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. Int J Mol Sci 2020;21:E6176. [PMID: 32867025 DOI: 10.3390/ijms21176176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
96 Jiang C, Wang H, Xia C, Dong Q, Chen E, Qiu Y, Su Y, Xie H, Zeng L, Kuang J, Ao F, Gong X, Li J, Chen T. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer 2019;125:1081-90. [PMID: 30521105 DOI: 10.1002/cncr.31907] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 11.7] [Reference Citation Analysis]
97 Özdemir BC, Dotto GP. Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin? Trends Cancer 2017;3:181-97. [PMID: 28718431 DOI: 10.1016/j.trecan.2017.02.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
98 Wu H, Cai L, Li D, Wang X, Zhao S, Zou F, Zhou K. Metagenomics Biomarkers Selected for Prediction of Three Different Diseases in Chinese Population. Biomed Res Int 2018;2018:2936257. [PMID: 29568746 DOI: 10.1155/2018/2936257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
99 Knezevic J, Starchl C, Tmava Berisha A, Amrein K. Thyroid-Gut-Axis: How Does the Microbiota Influence Thyroid Function? Nutrients 2020;12:E1769. [PMID: 32545596 DOI: 10.3390/nu12061769] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
100 Jacqueline C, Brazier L, Faugère D, Renaud F, Thomas F, Roche B. Can intestinal microbiota be associated with non-intestinal cancers? Sci Rep 2017;7:12722. [PMID: 28983086 DOI: 10.1038/s41598-017-11644-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
101 Diakite A, Dubourg G, Dione N, Afouda P, Bellali S, Ngom II, Valles C, Tall ML, Lagier JC, Raoult D. Optimization and standardization of the culturomics technique for human microbiome exploration. Sci Rep 2020;10:9674. [PMID: 32541790 DOI: 10.1038/s41598-020-66738-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
102 Xia C, Jiang C, Li W, Wei J, Hong H, Li J, Feng L, Wei H, Xin H, Chen T. A Phase II Randomized Clinical Trial and Mechanistic Studies Using Improved Probiotics to Prevent Oral Mucositis Induced by Concurrent Radiotherapy and Chemotherapy in Nasopharyngeal Carcinoma. Front Immunol 2021;12:618150. [PMID: 33841399 DOI: 10.3389/fimmu.2021.618150] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Reens AL, Cabral DJ, Liang X, Norton JE Jr, Therien AG, Hazuda DJ, Swaminathan G. Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. Front Immunol 2021;12:643255. [PMID: 34054810 DOI: 10.3389/fimmu.2021.643255] [Reference Citation Analysis]
104 Zhang X, Pan Z. Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers. Gastroenterol Rep (Oxf) 2020;8:206-14. [PMID: 32665852 DOI: 10.1093/gastro/goaa014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
105 Chilakapati SR, Ricciuti J, Zsiros E. Microbiome and cancer immunotherapy. Curr Opin Biotechnol 2020;65:114-7. [PMID: 32192986 DOI: 10.1016/j.copbio.2020.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
106 Boem F, Amedei A. Healthy axis: Towards an integrated view of the gut-brain health. World J Gastroenterol 2019;25:3838-41. [PMID: 31413521 DOI: 10.3748/wjg.v25.i29.3838] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
107 Wang W, Jin Y, Liu X, Chen F, Zheng X, Liu T, Yang Y, Yu H. Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer. Adv Funct Mater 2021;31:2100386. [DOI: 10.1002/adfm.202100386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
108 Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology 2017;6:e1373237. [PMID: 29147629 DOI: 10.1080/2162402X.2017.1373237] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
109 Cui JJ, Wang LY, Tan ZR, Zhou HH, Zhan X, Yin JY. MASS SPECTROMETRY-BASED PERSONALIZED DRUG THERAPY. Mass Spectrom Rev 2020;39:523-52. [PMID: 31904155 DOI: 10.1002/mas.21620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
110 Wang S, Xie K, Liu T. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters. Front Immunol 2021;12:690112. [PMID: 34367148 DOI: 10.3389/fimmu.2021.690112] [Reference Citation Analysis]
111 Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, Zhong J, Zeng J. Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. Front Cell Infect Microbiol 2018;8:167. [PMID: 29904624 DOI: 10.3389/fcimb.2018.00167] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 18.0] [Reference Citation Analysis]
112 Su M, Zhang Z, Zhou L, Han C, Huang C, Nice EC. Proteomics, Personalized Medicine and Cancer. Cancers (Basel) 2021;13:2512. [PMID: 34063807 DOI: 10.3390/cancers13112512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
113 Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol 2018;15:382-96. [PMID: 29636538 DOI: 10.1038/s41571-018-0006-2] [Cited by in Crossref: 167] [Cited by in F6Publishing: 139] [Article Influence: 83.5] [Reference Citation Analysis]
114 Pi H, Huang L, Liu H, Liang S, Mei J. Effects of PD-1/PD-L1 signaling pathway on intestinal flora in patients with colorectal cancer. Cancer Biomark 2020;28:529-35. [PMID: 32568184 DOI: 10.3233/CBM-201606] [Reference Citation Analysis]
115 Merlano MC, Granetto C, Fea E, Ricci V, Garrone O. Heterogeneity of colon cancer: from bench to bedside. ESMO Open 2017;2:e000218. [PMID: 29209524 DOI: 10.1136/esmoopen-2017-000218] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
116 Liu X, Chen Y, Zhang S, Dong L. Gut microbiota-mediated immunomodulation in tumor. J Exp Clin Cancer Res 2021;40:221. [PMID: 34217349 DOI: 10.1186/s13046-021-01983-x] [Reference Citation Analysis]
117 Mikó E, Kovács T, Sebő É, Tóth J, Csonka T, Ujlaki G, Sipos A, Szabó J, Méhes G, Bai P. Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored. Cells 2019;8:E293. [PMID: 30934972 DOI: 10.3390/cells8040293] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 23.0] [Reference Citation Analysis]
118 Scott AJ, Alexander JL, Merrifield CA, Cunningham D, Jobin C, Brown R, Alverdy J, O'Keefe SJ, Gaskins HR, Teare J, Yu J, Hughes DJ, Verstraelen H, Burton J, O'Toole PW, Rosenberg DW, Marchesi JR, Kinross JM. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut 2019;68:1624-32. [PMID: 31092590 DOI: 10.1136/gutjnl-2019-318556] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 36.0] [Reference Citation Analysis]
119 Hurez V, Padrón ÁS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol 2017;187:53-63. [PMID: 27690272 DOI: 10.1111/cei.12875] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 8.4] [Reference Citation Analysis]
120 Sepich-poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science 2021;371:eabc4552. [DOI: 10.1126/science.abc4552] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 27.0] [Reference Citation Analysis]
121 Rahmatika D, Kuroda N, Min Z, Nainu F, Nagaosa K, Nakanishi Y. Inhibitory effects of viral infection on cancer development. Virology 2019;528:48-53. [PMID: 30576859 DOI: 10.1016/j.virol.2018.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
122 Medjebar S, Truntzer C, Perrichet A, Limagne E, Fumet JD, Richard C, Elkrief A, Routy B, Rébé C, Ghiringhelli F. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. Oncoimmunology 2020;9:1836766. [PMID: 33178495 DOI: 10.1080/2162402X.2020.1836766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Baba Y, Iwatsuki M, Yoshida N, Watanabe M, Baba H. Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications. Ann Gastroenterol Surg. 2017;1:99-104. [PMID: 29863142 DOI: 10.1002/ags3.12014] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
124 Murphy WJ. Being "penny-wise but pound foolish" in cancer immunotherapy research: the urgent need for mouse cancer models to reflect human modifying factors. J Immunother Cancer 2016;4:88. [PMID: 28031818 DOI: 10.1186/s40425-016-0195-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Niccolai E, Russo E, Baldi S, Ricci F, Nannini G, Pedone M, Stingo FC, Taddei A, Ringressi MN, Bechi P, Mengoni A, Fani R, Bacci G, Fagorzi C, Chiellini C, Prisco D, Ramazzotti M, Amedei A. Significant and Conflicting Correlation of IL-9 With Prevotella and Bacteroides in Human Colorectal Cancer. Front Immunol 2020;11:573158. [PMID: 33488574 DOI: 10.3389/fimmu.2020.573158] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 McKenzie ND, Hong H, Ahmad S, Holloway RW. The gut microbiome and cancer immunotherapeutics: A review of emerging data and implications for future gynecologic cancer research. Crit Rev Oncol Hematol 2021;157:103165. [PMID: 33227575 DOI: 10.1016/j.critrevonc.2020.103165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
127 Stevens WB, Netea MG, Kater AP, van der Velden WJ. 'Trained immunity': consequences for lymphoid malignancies. Haematologica 2016;101:1460-8. [PMID: 27903713 DOI: 10.3324/haematol.2016.149252] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
128 Baffy G. Gut Microbiota and Cancer of the Host: Colliding Interests. Adv Exp Med Biol 2020;1219:93-107. [PMID: 32130695 DOI: 10.1007/978-3-030-34025-4_5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
129 Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM, Qu JM. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int J Cancer 2018;142:769-78. [PMID: 29023689 DOI: 10.1002/ijc.31098] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 14.5] [Reference Citation Analysis]
130 Dry JR, Yang M, Saez-Rodriguez J. Looking beyond the cancer cell for effective drug combinations. Genome Med 2016;8:125. [PMID: 27887656 DOI: 10.1186/s13073-016-0379-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
131 Singh A, Nayak N, Rathi P, Verma D, Sharma R, Chaudhary A, Agarwal A, Tripathi YB, Garg N. Microbiome and host crosstalk: A new paradigm to cancer therapy. Semin Cancer Biol 2021;70:71-84. [PMID: 32479952 DOI: 10.1016/j.semcancer.2020.05.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Yin J, Ren W, Huang X, Li T, Yin Y. Protein restriction and cancer. Biochim Biophys Acta Rev Cancer 2018;1869:256-62. [PMID: 29596961 DOI: 10.1016/j.bbcan.2018.03.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
133 Connolly C, Bambhania K, Naidoo J. Immune-Related Adverse Events: A Case-Based Approach. Front Oncol 2019;9:530. [PMID: 31293970 DOI: 10.3389/fonc.2019.00530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
134 Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bossé D, Steinharter JA, Martini DJ, Simantov R, Lin X, Wei XX, Mcgregor BA, Mckay RR, Harshman LC, Choueiri TK. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European Urology Oncology 2020;3:372-81. [DOI: 10.1016/j.euo.2019.09.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 24.0] [Reference Citation Analysis]
135 Han C, Kawata M, Hamada Y, Kondo T, Wada J, Asano K, Makabe H, Igarashi K, Kuzumaki N, Narita M, Kobayashi H, Narita M. Analyses of the possible anti-tumor effect of yokukansan. J Nat Med 2019;73:468-79. [PMID: 30739283 DOI: 10.1007/s11418-019-01283-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Cogdill AP, Gaudreau PO, Arora R, Gopalakrishnan V, Wargo JA. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol 2018;39:900-20. [PMID: 30392721 DOI: 10.1016/j.it.2018.09.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
137 Granato DC, Neves LX, Trino LD, Carnielli CM, Lopes AFB, Yokoo S, Pauletti BA, Domingues RR, Sá JO, Persinoti G, Paixão DAA, Rivera C, de Sá Patroni FM, Tommazetto G, Santos-Silva AR, Lopes MA, de Castro G Jr, Brandão TB, Prado-Ribeiro AC, Squina FM, Telles GP, Paes Leme AF. Meta-omics analysis indicates the saliva microbiome and its proteins associated with the prognosis of oral cancer patients. Biochim Biophys Acta Proteins Proteom 2021;1869:140659. [PMID: 33839314 DOI: 10.1016/j.bbapap.2021.140659] [Reference Citation Analysis]
138 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
139 Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front Immunol 2021;12:622064. [PMID: 33708214 DOI: 10.3389/fimmu.2021.622064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
140 D'Haens GR, Jobin C. Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection. Gastroenterology 2019;157:624-36. [PMID: 31220424 DOI: 10.1053/j.gastro.2019.04.053] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
141 Thomas F, Jacqueline C, Tissot T, Henard M, Blanchet S, Loot G, Dawson E, Mery F, Renaud F, Montagne J, Beckmann C, Biro PA, Hamede R, Ujvari B. The importance of cancer cells for animal evolutionary ecology. Nat Ecol Evol 2017;1:1592-5. [PMID: 29066812 DOI: 10.1038/s41559-017-0343-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
142 Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:31. [PMID: 29482595 DOI: 10.1186/s13045-018-0578-4] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 34.0] [Reference Citation Analysis]
143 Moaven O, Mangieri CW, Stauffer JA, Anastasiadis PZ, Borad MJ. Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. JCO Precis Oncol 2021;5:PO. [PMID: 34250395 DOI: 10.1200/PO.21.00003] [Reference Citation Analysis]
144 Zhang J, Zhang F, Zhao C, Xu Q, Liang C, Yang Y, Wang H, Shang Y, Wang Y, Mu X, Zhu D, Zhang C, Yang J, Yao M, Zhang L. Dysbiosis of the gut microbiome is associated with thyroid cancer and thyroid nodules and correlated with clinical index of thyroid function. Endocrine 2019;64:564-74. [PMID: 30584647 DOI: 10.1007/s12020-018-1831-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
145 Bai J, Behera M, Bruner DW. The gut microbiome, symptoms, and targeted interventions in children with cancer: a systematic review. Support Care Cancer 2018;26:427-39. [PMID: 29168036 DOI: 10.1007/s00520-017-3982-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
146 Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. Trends in Immunology 2017;38:577-93. [DOI: 10.1016/j.it.2017.05.006] [Cited by in Crossref: 159] [Cited by in F6Publishing: 145] [Article Influence: 39.8] [Reference Citation Analysis]
147 Marzullo P, Bettini S, Menafra D, Aprano S, Muscogiuri G, Barrea L, Savastano S, Colao A; Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Spot-light on microbiota in obesity and cancer. Int J Obes (Lond) 2021. [PMID: 34363002 DOI: 10.1038/s41366-021-00866-7] [Reference Citation Analysis]
148 Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437-1444. [PMID: 29617710 DOI: 10.1093/annonc/mdy103] [Cited by in Crossref: 293] [Cited by in F6Publishing: 259] [Article Influence: 146.5] [Reference Citation Analysis]
149 Lopetuso LR, Severgnini M, Pecere S, Ponziani FR, Boskoski I, Larghi A, Quaranta G, Masucci L, Ianiro G, Camboni T, Gasbarrini A, Costamagna G, Consolandi C, Cammarota G. Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. PLoS One. 2020;15:e0231789. [PMID: 32369505 DOI: 10.1371/journal.pone.0231789] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
150 Pan H, Zheng M, Ma A, Liu L, Cai L. Cell/Bacteria-Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy. Adv Mater 2021;:e2100241. [PMID: 34121236 DOI: 10.1002/adma.202100241] [Reference Citation Analysis]
151 Ran Z, Liu J, Wang F, Xin C, Xiong B, Song Z. Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients. Front Oncol 2020;10:576855. [PMID: 33537234 DOI: 10.3389/fonc.2020.576855] [Reference Citation Analysis]
152 Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. Nat Rev Cancer 2018;18:283-95. [PMID: 29449660 DOI: 10.1038/nrc.2018.10] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 29.3] [Reference Citation Analysis]
153 Barsac E, de Amat Herbozo C, Gonzalez L, Baranek T, Mallevaey T, Paget C. Regulation and Functions of Protumoral Unconventional T Cells in Solid Tumors. Cancers (Basel) 2021;13:3578. [PMID: 34298791 DOI: 10.3390/cancers13143578] [Reference Citation Analysis]
154 Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology 2017;6:e1328341. [PMID: 28811970 DOI: 10.1080/2162402X.2017.1328341] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 12.5] [Reference Citation Analysis]
155 Li Y, Su X, Zhang L, Liu Y, Shi M, Lv C, Gao Y, Xu D, Wang Z. Dysbiosis of the gut microbiome is associated with CKD5 and correlated with clinical indices of the disease: a case-controlled study. J Transl Med 2019;17:228. [PMID: 31315634 DOI: 10.1186/s12967-019-1969-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
156 Niccolai E, Boem F, Emmi G, Amedei A. The link “Cancer and autoimmune diseases” in the light of microbiota: Evidence of a potential culprit. Immunology Letters 2020;222:12-28. [DOI: 10.1016/j.imlet.2020.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
157 Kovács T, Mikó E, Ujlaki G, Sári Z, Bai P. The Microbiome as a Component of the Tumor Microenvironment. Adv Exp Med Biol 2020;1225:137-53. [PMID: 32030653 DOI: 10.1007/978-3-030-35727-6_10] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
158 Hill AA, Diehl GE. Identifying the Patterns of Pattern Recognition Receptors. Immunity 2018;49:389-91. [PMID: 30231979 DOI: 10.1016/j.immuni.2018.08.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
159 Akrami M, Menzies R, Chamoto K, Miyajima M, Suzuki R, Sato H, Nishii A, Tomura M, Fagarasan S, Honjo T. Circulation of gut-preactivated naïve CD8+ T cells enhances antitumor immunity in B cell-defective mice. Proc Natl Acad Sci U S A 2020;117:23674-83. [PMID: 32907933 DOI: 10.1073/pnas.2010981117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
160 Chen KL, Jung P, Kulkoyluoglu-Cotul E, Liguori C, Lumibao J, Mazewski C, Ranard K, Rowles JL 3rd, Wang Y, Xue L, Madak-Erdogan Z. Impact of Diet and Nutrition on Cancer Hallmarks. J Cancer Prev Curr Res 2017;7:240. [PMID: 30581989 DOI: 10.15406/jcpcr.2017.07.00240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Liu Y, Li Z, Wu Y, Jing X, Li L, Fang X. Intestinal Bacteria Encapsulated by Biomaterials Enhance Immunotherapy. Front Immunol 2020;11:620170. [PMID: 33643302 DOI: 10.3389/fimmu.2020.620170] [Reference Citation Analysis]
162 Jin J, Gan Y, Liu H, Wang Z, Yuan J, Deng T, Zhou Y, Zhu Y, Zhu H, Yang S, Shen W, Xie D, Wu H, Liu D, Li W. Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation. Lung Cancer 2019;136:129-35. [PMID: 31494531 DOI: 10.1016/j.lungcan.2019.08.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
163 Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T. Identification of non-mutated neoantigens presented by TAP-deficient tumors. J Exp Med 2018;215:2325-37. [PMID: 30115740 DOI: 10.1084/jem.20180577] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
164 Xing C, Wang M, Ajibade AA, Tan P, Fu C, Chen L, Zhu M, Hao ZZ, Chu J, Yu X, Yin B, Zhu J, Shen WJ, Duan T, Wang HY, Wang RF. Microbiota regulate innate immune signaling and protective immunity against cancer. Cell Host Microbe 2021;29:959-974.e7. [PMID: 33894128 DOI: 10.1016/j.chom.2021.03.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
165 Ejby M, Guskov A, Pichler MJ, Zanten GC, Schoof E, Saburi W, Slotboom DJ, Abou Hachem M. Two binding proteins of the ABC transporter that confers growth of Bifidobacterium animalis subsp. lactis ATCC27673 on β-mannan possess distinct manno-oligosaccharide-binding profiles. Mol Microbiol 2019;112:114-30. [PMID: 30947380 DOI: 10.1111/mmi.14257] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
166 Routy JP, Routy B, Graziani GM, Mehraj V. The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy. Int J Tryptophan Res 2016;9:67-77. [PMID: 27773992 DOI: 10.4137/IJTR.S38355] [Cited by in Crossref: 81] [Cited by in F6Publishing: 37] [Article Influence: 16.2] [Reference Citation Analysis]
167 Gharaibeh RZ, Jobin C. Microbiota and cancer immunotherapy: in search of microbial signals. Gut 2019;68:385-8. [PMID: 30530851 DOI: 10.1136/gutjnl-2018-317220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 11.3] [Reference Citation Analysis]
168 Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 2017;66:551-64. [DOI: 10.1007/s00262-017-1954-6] [Cited by in Crossref: 162] [Cited by in F6Publishing: 151] [Article Influence: 40.5] [Reference Citation Analysis]
169 Shah RM, McKenzie EJ, Rosin MT, Jadhav SR, Gondalia SV, Rosendale D, Beale DJ. An Integrated Multi-Disciplinary Perspectivefor Addressing Challenges of the Human Gut Microbiome. Metabolites 2020;10:E94. [PMID: 32155792 DOI: 10.3390/metabo10030094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
170 Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity 2016;44:1255-69. [PMID: 27332730 DOI: 10.1016/j.immuni.2016.06.001] [Cited by in Crossref: 438] [Cited by in F6Publishing: 409] [Article Influence: 109.5] [Reference Citation Analysis]
171 Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17:271-285. [PMID: 28303904 DOI: 10.1038/nrc.2017.13] [Cited by in Crossref: 370] [Cited by in F6Publishing: 321] [Article Influence: 92.5] [Reference Citation Analysis]
172 Buono R, Longo VD. Starvation, Stress Resistance, and Cancer. Trends Endocrinol Metab 2018;29:271-80. [PMID: 29463451 DOI: 10.1016/j.tem.2018.01.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 15.3] [Reference Citation Analysis]
173 Peruhova M, Peshevska-Sekulovska M, Krastev B, Panayotova G, Georgieva V, Konakchieva R, Nikolaev G, Velikova TV. What could microRNA expression tell us more about colorectal serrated pathway carcinogenesis? World J Gastroenterol. 2020;26:6556-6571. [PMID: 33268946 DOI: 10.3748/wjg.v26.i42.6556] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
174 Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX, Weichselbaum RR. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med 2021;218:e20201915. [PMID: 33496784 DOI: 10.1084/jem.20201915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
175 Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. BMC Cancer 2020;20:383. [PMID: 32375706 DOI: 10.1186/s12885-020-06882-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
176 El Sayed R, Haibe Y, Amhaz G, Bouferraa Y, Shamseddine A. Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level? Int J Mol Sci 2021;22:2142. [PMID: 33670011 DOI: 10.3390/ijms22042142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Chen X, Li HY, Hu XM, Zhang Y, Zhang SY. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure. Chin Med J (Engl) 2019;132:1843-55. [PMID: 31306229 DOI: 10.1097/CM9.0000000000000330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
178 Chen W, Wang S, Wu Y, Shen X, Guo Z, Li Q, Xing D. Immunogenic cell death: A link between gut microbiota and anticancer effects. Microbial Pathogenesis 2020;141:103983. [DOI: 10.1016/j.micpath.2020.103983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]